These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37702920)

  • 21. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.
    Nichols RM; Macpherson L; Patel DR; Yeh WW; Peppercorn A
    Infect Dis Ther; 2024 Feb; 13(2):401-411. PubMed ID: 38291279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records.
    Bell CF; Gibbons DC; Drysdale M; Birch HJ; Lloyd EJ; Patel V; Carpenter C; Carlson K; Calay ES; Puranik A; Wagner TE; O'Horo JC; Razonable RR
    PLoS One; 2024; 19(7):e0304822. PubMed ID: 39012863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial.
    Shapiro AE; Sarkis E; Acloque J; Free A; Gonzalez-Rojas Y; Hussain R; Juarez E; Moya J; Parikh N; Inman D; Cebrik D; Nader A; Noormohamed N; Wang Q; Skingsley A; Austin D; Peppercorn A; Agostini ML; Parra S; Chow S; Mogalian E; Pang PS; Hong DK; Sager JE; Yeh WW; Alexander EL; Gaffney LA; Kohli A
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad354. PubMed ID: 37577112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Wogu AF; Wynia MK; Zane RD; Ginde AA
    J Infect Dis; 2022 Dec; 226(12):2129-2136. PubMed ID: 35576581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
    Lo CKL; Lo CKF; Komorowski AS; Leung V; Matic N; McKenna S; Perez-Patrigeon S; Sheth PM; Lowe CF; Chagla Z; Bai AD
    BMC Res Notes; 2024 Jan; 17(1):37. PubMed ID: 38267971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.
    Drysdale M; Hautekiet T; Singh M; Hautekiet J; Ludikhuyze L; Patel V; Gibbons DC; De Roeck D; Colpaert K; Lloyd EJ; Van Braeckel E
    Acta Clin Belg; 2024 Jun; 79(3):174-183. PubMed ID: 39081095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge.
    Piccicacco N; Zeitler K; Ing A; Montero J; Faughn J; Silbert S; Kim K
    J Antimicrob Chemother; 2022 Sep; 77(10):2693-2700. PubMed ID: 35913836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.
    Seethamraju H; Yang OO; Loftus R; Ogbuagu O; Sammartino D; Mansour A; Sacha JB; Ojha S; Hansen SG; Arman AC; Lalezari JP
    Clin Ther; 2024 Nov; 46(11):891-899. PubMed ID: 39353749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial.
    Chew KW; Moser C; Daar ES; Wohl DA; Li JZ; Coombs R; Ritz J; Giganti M; Javan AC; Li Y; Malvestutto C; Klekotka P; Price K; Nirula A; Fischer W; Bala V; Ribeiro RM; Perelson AS; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM;
    medRxiv; 2021 Dec; ():. PubMed ID: 34981077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis.
    Farhadian N; Farhadian M; Zamanian MH; Taghadosi M; Vaziri S
    Immunopharmacol Immunotoxicol; 2023 Dec; 45(4):402-408. PubMed ID: 36537311
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste.
    Chupp G; Spichler-Moffarah A; Søgaard OS; Esserman D; Dziura J; Danzig L; Chaurasia R; Patra KP; Salovey A; Nunez A; May J; Astorino L; Patel A; Halene S; Wang J; Hui P; Patel P; Lu J; Li F; Gan G; Parziale S; Katsovich L; Desir GV; Vinetz JM
    medRxiv; 2022 Jan; ():. PubMed ID: 35132421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19.
    Sager JE; El-Zailik A; Passarell J; Roepcke S; Li X; Aldinger M; Nader A; Skingsley A; Alexander EL; Yeh WW; Mogalian E; Garner C; Peppercorn A; Shapiro AE; Reyes M
    CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):853-864. PubMed ID: 36922886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.
    Gonzalez-Bocco IH; Beluch K; Cho A; Lahoud C; Reyes FA; Moshovitis DG; Unger-Mochrie GM; Wang W; Hammond SP; Manne-Goehler J; Koo S
    Pilot Feasibility Stud; 2023 Jun; 9(1):100. PubMed ID: 37328890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.